AHSA1通过TGF-β/Akt-Cyclin D1/CDK6通路调节肝细胞癌的进展
Yanjun Gao1,2, Yingge Li1,2, Zheming Liu1,2
1Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.
Journal of hepatocellular carcinoma
|November 29, 2023
概括
热冲击蛋白90ATPase活性1 (AHSA1) 的激活剂促进肝细胞癌 (HCC) 的进展和转移. 高AHSA1表达预测患者的生存率很低,这表明它有可能成为HCC的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 热冲击蛋白90ATPase活性1 (AHSA1) 的激活剂与癌症有关,但其在肝细胞癌 (HCC) 瘤生物学中的具体作用尚未完全理解.
- 在各种癌症中,AHSA1调节关键的细胞过程,包括增殖,亡,迁移和入侵.
研究的目的:
- 阐明AHSA1在肝细胞癌 (HCC) 进展中的新机制.
- 为了研究AHSA1在HCC患者的预后价值.
主要方法:
- 临床HCC样本中的AHSA1表达分析和癌症基因组图谱数据库.
- 在体外测试 (繁殖,殖民地形成,迁移,细胞循环) 和体内研究 (异种移植模型,转移测试) 确定AHSA1的功能作用.
- 生物信息分析,包括基因表达简介交互分析,以探索信号通路.
主要成果:
- 在HCC中,高AHSA1表达与侵袭深度,晚期临床阶段和降低整体存活率相关.
- AHSA1上调促进HCC细胞的增殖,迁移和转移在体外和体内.
- AHSA1通过上调循环D1,循环D3和CDK6,可能通过TGF-β/Akt信号通路来增强细胞循环进展.
结论:
- AHSA1是HCC患者的独立预后因素,在瘤转移和进展中起着关键作用.
- AHSA1可以作为一个有价值的生物标志物来预测HCC的临床结果.
- 针对AHSA1可能为HCC干预提供潜在的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K


